<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H995AC0B3BFE8431F9505DD9A7C03E87D" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>117 HR 7035 IH: Biologics Market Transparency Act of 2022</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2022-03-09</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">117th CONGRESS</congress><session display="yes">2d Session</session><legis-num display="yes">H. R. 7035</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20220309">March 9, 2022</action-date><action-desc><sponsor name-id="M001135">Ms. Manning</sponsor> (for herself and <cosponsor name-id="H001067">Mr. Hudson</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend the Federal Food, Drug, and Cosmetic Act to require prompt reports of marketing status by holders of approved applications for biological products, and for other purposes.</official-title></form><legis-body id="H1CAF5CA6B3104FA8A09765E3982030A9" style="OLC"><section id="H34FE2E6F7CE147698493613C1E99BEB2" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Biologics Market Transparency Act of 2022</short-title></quote> .</text></section><section id="HE3E22151B11F406694D32261A1A80898"><enum>2.</enum><header>Prompt reports of marketing status by holders of approved applications for biological products</header><subsection id="H030329D48F704C68858CB6AC24D3B110"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Section 506I of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/356i">21 U.S.C. 356i</external-xref>) is amended—</text><paragraph id="HD9AB06B65D4E4A8BB5780FD466B3312D"><enum>(1)</enum><text>in subsection (a)—</text><subparagraph id="H051E40CECF3741FABDE3C69AB56447F4"><enum>(A)</enum><text>by striking <quote>The holder of an application approved under subsection (c) or (j) of section 505</quote> and inserting <quote>The holder of an application approved under subsection (c) or (j) of section 505 of this Act or subsection (a) or (k) of section 351 of the Public Health Service Act</quote>; and</text></subparagraph><subparagraph id="H8EB80A8D02C946CD9D25C76A1F85EC59"><enum>(B)</enum><text>in paragraph (3), by striking <quote>or abbreviated application number</quote> and inserting <quote>, abbreviated application number, or biologics license application number</quote>; and </text></subparagraph></paragraph><paragraph id="H9C4F67FD6A9D43AB94292763183C920F"><enum>(2)</enum><text>in subsection (b)—</text><subparagraph id="H9513661CE63E4C378FFFD5DC60530AD5"><enum>(A)</enum><text>by striking <quote>The holder of an application approved under subsection (c) or (j)</quote> and inserting <quote>The holder of an application approved under subsection (c) or (j) of section 505 of this Act or subsection (a) or (k) of section 351 of the Public Health Service Act</quote>; and</text></subparagraph><subparagraph id="H6CF5850847C64FBE8D9287180A34C147"><enum>(B)</enum><text display-inline="yes-display-inline">in paragraph (2), by striking <quote>or abbreviated application number</quote> and inserting <quote>, abbreviated application number, or biologics license application number</quote>.</text></subparagraph></paragraph></subsection><subsection id="H558857A3CCC54F059E250D4E50887BF1"><enum>(b)</enum><header>Additional one-Time report</header><text display-inline="yes-display-inline">Subsection (c) of section 506I of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/356i">21 U.S.C. 356i</external-xref>) is amended to read as follows:</text><quoted-block style="OLC" id="H8AAD3471419C4285A34732F40BA873D8" display-inline="no-display-inline"><subsection id="HD8AF341C6B69421F8887F958C12D2122"><enum>(c)</enum><header>Additional one-Time report</header><text display-inline="yes-display-inline">Within 180 days of the date of enactment of the <short-title>Biologics Market Transparency Act of 2022</short-title>, all holders of applications approved under subsection (a) or (k) of section 351 of the Public Health Service Act shall review the information in the list published under section 351(k)(9)(A) and shall submit a written notice to the Secretary—</text><paragraph id="H5F5AF77B60A143F499408036A99BDA06"><enum>(1)</enum><text display-inline="yes-display-inline">stating that all of the application holder’s biological products in the list published under section 351(k)(9)(a) that are not listed as discontinued are available for sale; or</text></paragraph><paragraph id="H69832412F0F042F58DFCCFA2EB6689A7"><enum>(2)</enum><text display-inline="yes-display-inline">including the information required pursuant to subsection (a) or (b), as applicable, for each of the application holder’s biological products that are in the list published under section 351(k)(9)(a) and not listed as discontinued, but have been withdrawn from sale or never have been available for sale.</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="HBB2EC8B65B954733BD5D02F31AAC6323"><enum>(c)</enum><header>Purple Book</header><text display-inline="yes-display-inline">Subsections (d) and (e) of section 506I of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/356i">21 U.S.C. 356i</external-xref>) are each amended—</text><paragraph id="H5DE0A93D1B0F480CB243223A30E1D494"><enum>(1)</enum><text>by striking <quote>the list published under subsection 505(j)(7)(A)</quote> and inserting <quote>the list published under section 505(j)(7)(A) of this Act or section 351(k)(9)(A) of the Public Health Service Act, as applicable,</quote>; and</text></paragraph><paragraph id="HCB5488AADD9A4DA3B94B0EEC62ECB142"><enum>(2)</enum><text display-inline="yes-display-inline">by striking <quote>in accordance with subsection 505(j)(7)(C)</quote> and inserting <quote>in accordance with section 505(j)(7)(C) of this Act or section 351(k)(9)(B) of the Public Health Service Act (as applicable)</quote>.</text></paragraph></subsection></section></legis-body></bill> 

